- Clinical research is consolidating itself as one of the strategic pillars of the healthcare group, and for this purpose, structures have been strengthened to promote multicenter trials, studies and projects that bring therapeutic alternatives closer to its patients.
- Ribera's research network is growing in all its hospitals thanks to the current management's commitment to innovation, medical talent, and its responsible healthcare model.
Clinical research has become established as one of the main strategic pillars of the healthcare group. RiberaWithin its responsible healthcare model and its commitment to healthcare innovation, medical excellence, and the generation of scientific knowledge, the Ribera Group managed a total of 77 clinical trials across its various hospitals and 63 observational studies during 2025, in addition to 264 scientific publications and multicenter collaborative projects in different specialties.
In the context of International Clinical Trials Day, Ribera highlights the development of this activity, which is carried out through its corporate Research area, comprised of 144 research professionals within the group and considered the organization's knowledge center. This area has been designed to provide Ribera's healthcare professionals with technical resources, methodological support, analytical tools, and governance procedures that enable them to optimize research results and bring innovative therapeutic alternatives to patients.
Mercedes Gozalbo, Corporate Director of Research at the Ribera healthcare group, explains that “in the research area, together with our professionals, we promote clinical research studies and projects, and we have the necessary resources, tools, and methodology to facilitate clinical trials, observational studies, and high-impact scientific publications.”
Specialties and hospitals with the highest research activity
Among the hospitals managed by the Ribera group with the highest research activity, the following stand out: Torrejón University HospitalWith 34 clinical trials and 28 observational studies planned for 2025, the areas of Cardiology, Oncology, Neurology, Gastroenterology, and Obstetrics are leading the way in clinical trials and observational studies. Other specialties in Torrejón conducting cutting-edge research include Dermatology, Internal Medicine, Intensive Care Medicine, Pediatrics, and Pulmonology.
Torrejón is followed in terms of research activity in clinical trials and observational studies by the University Hospital of Vinalopowith 12 clinical trials and 16 observational studies managed in 2025. In the case of this hospital of the group, located in Elche, the areas of Hematology, Medical Oncology, Neurology and Allergology are the most outstanding and prolific.
Hospital Ribera PovisaFor its part, it registered six clinical trials and six observational studies in 2025, with a strong presence in the areas of Internal Medicine, Neurology, Allergology, and Pulmonology, in addition to Medical Oncology. And finally, Ribera Polusa It closed 2025 with seven clinical trials and one observational study, all of them related to the area of Nephrology.
For Mercedes Gozalbo, “research is part of Ribera’s DNA and is a fundamental tool to continue improving healthcare, promoting medical innovation and offering new therapeutic opportunities to our patients.”
Research talent and ability to attract
One of the most significant aspects of the Ribera healthcare group's research growth is the consolidation of a broad network of professionals involved in high-level scientific and clinical activity. Currently, 144 researchers participate in various projects and publications developed at the group's hospitals, a number that continues to grow and reinforces Ribera's position as a highly attractive organization for healthcare professionals with a research focus.
“We have a large and important network of Ribera researchers made up of professionals from our hospitals, which grows every month and is itself a magnet for highly valuable healthcare professionals for our work,” says Mercedes Gozalbo, who also emphasizes the importance of offering therapeutic alternatives to patients with complex pathologies in their reference hospitals.
In addition to clinical research, the Ribera group maintains an intense scientific dissemination activity aimed at sharing medical knowledge and reinforcing the organization's commitment to responsible, innovative and evidence-based healthcare.
